Eris Lifesciences , a prominent player in the pharmaceuticals sector, has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The company's Board of Directors approved these results in a meeting held on November 12, 2025.

Financial Performance

For the quarter ended September 30, 2025 (Q2 FY26), Eris Lifesciences reported the following key financial metrics:

The company demonstrated strong growth across all major financial indicators. Notably, the net profit saw a substantial increase compared to the same quarter in the previous year.

Operational Highlights

• The Operating Profit Margin (OPM) improved to 36.2%, showing a significant increase of 40.36% compared to the same period last year.
• Other income for the quarter stood at ₹22.70 crore, representing a 336.54% increase year-over-year.
• The company's expenses rose by 8.70% to ₹362.30 crore, which is notably lower than the revenue growth rate, indicating improved operational efficiency.

Board Approvals and Corporate Actions

In addition to the financial results, the Board of Directors made several key decisions:

1. Director Reappointments:

   • Mr. Krishnakumar Vaidyanathan has been recommended for reappointment as Whole Time Director for a 5-year term from September 1, 2026, to August 31, 2031.
   • Ms. Kalpana Unadkat has been recommended for reappointment as Independent Director for a 5-year term from January 5, 2026, to January 4, 2031.

2. Employee Stock Option Scheme: The company issued 50,985 ordinary shares under its Employee Stock Option Scheme 2021 during the half-year period. This action has increased the paid-up share capital to ₹13.62 crore.

Business Segment

Eris Lifesciences continues to operate primarily in the pharmaceuticals business segment. The financial performance, coupled with strategic board decisions, may influence the company's operations in the coming years.

The reappointment of key directors suggests a focus on maintaining leadership continuity, which may contribute to the company's long-term strategic planning and execution.

In a significant development for the pharmaceutical industry, the Indian Patent Office has revoked Novartis' patent for Vymada, also known as Entresto, a widely used cardiac medication. This decision marks a pivotal moment in the ongoing debate over drug patents and accessibility to affordable healthcare in India.

Impact on Generic Drug Manufacturers

The cancellation of Novartis' patent opens the door for generic drug manufacturers to enter the market. This move is expected to lead to the production and distribution of more affordable versions of the life-saving cardiac medication.

Implications for Patients and Healthcare

The availability of generic versions of Vymada could potentially result in:

• Increased accessibility to the medication for patients with heart conditions
• Reduced healthcare costs for individuals and healthcare systems
• Greater competition in the cardiac drug market

Novartis' Position

Novartis has not yet commented on this development. The decision is likely to impact the company's market share and revenue from Vymada in India.

Broader Context

This case highlights the ongoing tension between pharmaceutical innovation and drug accessibility, particularly in developing countries. India's patent laws and their interpretation have been a subject of debate, with the country often prioritizing public health concerns over pharmaceutical companies' patent rights.

The cancellation of the Vymada patent adds to a series of similar decisions by Indian authorities, reinforcing the country's stance on balancing innovation incentives with the need for affordable medicines.

As this situation unfolds, it will be crucial to monitor how it affects:

• The availability and pricing of Vymada and its generic equivalents in India
• Novartis' strategy in the Indian market
• The broader implications for international pharmaceutical companies operating in India

This development serves as a reminder of the complex interplay between intellectual property rights, public health policies, and access to essential medications in the global pharmaceutical landscape.